Crizotinib, targeting multiple alterations, including ALK, MET, and ROS1, received accelerated FDA approval in 2011 for ALK-rearranged NSCLC due to impressive results from phase I and II trials [17]. This evidence concerns the gene ALK and non-small cell lung carcinoma.